跳至主要内容
临床试验/NCT07319923
NCT07319923招募中不适用

Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing

Peking University First Hospital1 个研究点 分布在 1 个国家目标入组 3,000 人开始时间: 2024年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
3,000
试验地点
1
主要终点
Serum PSA level

研究概览

简要总结

Prostate cancer is one of the most common malignancies in the male genitourinary system, and it is also the cancer with the fastest-growing incidence and mortality rates among men in China. Although prostate cancer screening can significantly reduce mortality, China has not yet established a well-developed screening system, which is one of the reasons why its mortality rate remains notably higher than that of Western countries. The primary objective of this project is to establish an efficient screening-diagnosis-treatment pathway, beginning with screening in community hospitals, followed by definitive diagnosis in secondary hospitals, and finally treatment in tertiary hospitals. Additionally, the project aims to achieve multi-institutional and multi-terminal sharing of disease information as well as dynamic monitoring and follow-up. The feasibility and effectiveness of this model will be validated through statistical analysis of the data.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male community residents aged 50 years or older;
  • Life expectancy > 10 years and ECOG performance status of 0-2;
  • Permanent residents of Beijing who are willing to cooperate with researchers in the screening process, complete required tests and questionnaires, and participate in subsequent follow-up;
  • Support for the research project and provision of signed informed consent.

排除标准

  • 1)Presence of any other malignant tumor or pre-existing prostate malignancy; 2)Presence of prostatitis or active infection in other parts of the urinary system; 3)Inability to cooperate with the study procedures or other factors deemed unsuitable for participation in this study.

结局指标

主要结局

Serum PSA level

时间窗: from 2025 to 2027

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Establishment and Promotion of an AI-Based Early... | 临床试验